Role of adjuvant chemotherapy after concurrent chemoradiotherapy in patients with locally advanced cervical cancer

作者全名："Kou, Lingna; Zhang, Tao; Yang, Xiling; Peng, Siyun; Wang, Yifei; Yuan, Mingyang; Li, Minmin"

作者地址："[Kou, Lingna; Zhang, Tao; Yuan, Mingyang; Li, Minmin] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing 400010, Peoples R China; [Kou, Lingna; Zhang, Tao] Univ Elect Sci & Technol, Sichuan Canc Hosp & Inst, Sch Med, Sichuan Canc Ctr,Dept Med Oncol, Chengdu 610041, Peoples R China; [Yang, Xiling] Univ Elect Sci & Technol China, Chengdu Womens & Childrens Cent Hosp, Sch Med, Dept Radiat Oncol, Chengdu 610031, Peoples R China; [Peng, Siyun] Indiana Univ, Dept Sociol, Bloomington, IN 47405 USA; [Wang, Yifei] Jiulongpo Peoples Hosp Chongqing, Dept Oncol, Chongqing 400050, Peoples R China"

通信作者："Li, MM (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing 400010, Peoples R China."

来源：FUTURE ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000759462100001

JCR分区：Q3

影响因子：3.3

年份：2022

卷号：18

期号：16

开始页：1917

结束页：1926

文献类型：Article

关键词：adjuvant chemotherapy; cervical cancer; chemoradiotherapy

摘要："Objectives: With the use of concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC), survival outcomes are still not optimal. This study was designed to evaluate the efficacy and safety of adjuvant chemotherapy (ACT) for patients with LACC after treatment with CCRT. Methods: Patients diagnosed with stage IIA-IIIB LACC, were retrospectively analyzed. All patients received cisplatin-based CCRT and were divided into two groups: ACT after CCRT (CCRT + ACT group) and observation after CCRT (CCRT group). Overall survival (OS), progression-free survival (PFS) and adverse effects were recorded and analyzed. Results: In total, 375 patients were included; 262 patients accepted ACT after CCRT while the remaining 113 patients chose observation. With a median follow-up of 40 months, no significant differences were found in the OS rates for patients in the CCRT + ACT and CCRT groups at 1 year, 3 years and the end of follow-up. There was also no significant discrepancy in PFS between groups. Subgroup analysis showed the International Federation of Gynecology and Obstetrics (FIGO) stage and age had negligible influence on both OS and PFS. Acute adverse events (grades 3-4) happened more frequently in CCRT + ACT group than in the CCRT group, with significant differences in neutropenia, anemia and creatinine. Conclusion: ACT after CCRT did not show benefit in survival but did induce some adverse effects. Therefore, this regimen is not recommended unless further large-scale randomized controlled trials are executed."

基金机构：Natural Science Foundation of Chongqing [20190101]

基金资助正文：The study was supported by the Natural Science Foundation of Chongqing (grant number 20190101). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.